Table 4 Interobserver reproducibility assessed in two cohorts of ankylosing spondylitis (AS) patients
Patient cohortNo of patientsNo. of observersInterobserver ICC (95% CI)
FORCAST4220.96 (0.93 to 0.98)
Adalimumab trial226*
    SPARCC0.89 (0.77 to 0.94) status
0.77 (0.36 to 0.92) change
    MASES0.81 (0.59 to 0.91) status
0.25 (–1.14 to 0.74) change

  • *Three sites (two per site).

  • FORCAST, Follow-Up Research Cohort of AS longitudinal study; MASES, Maastricht AS Enthesitis Score SPARCC, Spondyloarthritis Research Consortium of Canada.